| 摘要 |
Lupus erythematosus can be treated by administering therapeutic amounts of DELTA5-androstene-3beta-ol-7,17-dione and metabolizable precursors thereof, such as DELTA5-androstene-3beta-acetoxy-7,17-dione, which are readily metabolized in vivo to DELTA5-androstene-3beta-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature. |
